All In Biotech

NDA 208984 · Viiv Hlthcare

Selzentry

Maraviroc · Oral · CCR5 Co-receptor Antagonist

Priority review

Last checked: Nov 20, 2026Latest source record: Oct 30, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

Nov 4, 2016

Approved uses

2

Original approval plus efficacy supplements

Registered trials

146

32 Phase 3, 6 recruiting

FAERS reports

2,293

1,961 serious, 264 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: HEPATOTOXICITY Hepatotoxicity has been reported with use of SELZENTRY. Severe rash or evidence of a systemic allergic reaction (e.g., fever, eosinophilia, or elevated IgE) prior to the development of hepatotoxicity may occur. Patients with signs or symptoms of hepatitis or allergic reaction following use of SELZENTRY should be evaluated immediately [see Warnings and Precautions ( 5.1 )] . WARNING: HEPATOTOXICITY See full prescribing information for complete boxed warning. • Hepatotoxicity has been reported which may be preceded by severe rash or other features of a systemic allergic reaction (e.g., fever, eosinophilia, or elevated IgE). ( 5.1 ) • Immediately evaluate patients with signs or symptoms of hepatitis or allergic reaction. ( 5.1 )

What it is approved for

From the label in effect Sep 26, 2022.

SELZENTRY is indicated in combination with other antiretroviral agents for the treatment of only CCR5‑tropic human immunodeficiency virus type 1 (HIV‑1) infection in adult and pediatric patients weighing at least 2 kg. Limitations of Use • SELZENTRY is not recommended in patients with dual/mixed- or CXCR4-tropic HIV-1 [see Microbiology ( 12.4 )]. SELZENTRY is a CCR5 co-receptor antagonist indicated in combination with other antiretroviral agents for the treatment of only CCR5-tropic HIV-1 infection in adults and pediatric patients weighing at least 2 kg. ( 1 ) Limitations of Use: • Not recommended in patients with dual/mixed- or CXCR4-tropic HIV-1. ( 1 )

Mechanism: Maraviroc is an HIV-1 antiviral drug [see Microbiology ( 12.4 )] .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • SELZENTRY · MARAVIROC 20MG/ML · SOLUTION, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Maraviroc" as an intervention, any sponsor and status, largest first.

All 146 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • virologic failure141
  • viral mutation identified128
  • pathogen resistance125
  • pain95
  • anxiety94
  • off label use94
  • drug ineffective93
  • drug interaction86
  • drug resistance85
  • emotional distress73
  • nausea73
  • treatment failure64

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200711
200886
2009151
2010164
2011138
2012156
2013124
2014120
2015140
2016185
2017133
2018128
2019108
2020118
2021140
2022120
2023124
202464
202549
202634

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • To Be Discontinued · updated Jan 20, 2026

    Selzentry, Solution, 20 mg/mL Oral Solution Kit | 230 mL Oral Solution per Bottle | 1 Bottle per Carton (NDC 49702-260-55). The anticipated date that GSK will cease distribution of the product is approximately August...

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Selzentry (Maraviroc)

2024 spending

$4.1M

Beneficiaries

346

2,034 claims

Per beneficiary

$11,836

$27.28 per unit

View as table
YearSpending
2020$43,522,989
2021$40,068,272
2022$27,060,225
2023$8,700,940
2024$4,095,168

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 166 on PubMed

Sponsor: GSK

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.